These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31140829)

  • 61. A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma.
    Sun CY; Su TF; Li N; Zhou B; Guo ES; Yang ZY; Liao J; Ding D; Xu Q; Lu H; Meng L; Wang SX; Zhou JF; Xing H; Weng DH; Ma D; Chen G
    Oncotarget; 2016 Jan; 7(3):3245-54. PubMed ID: 26675546
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
    Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
    Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.
    Guo W; He X; Ni J; Ma L; Cheng X; Wang C; Chen X; Wang Y
    Front Oncol; 2021; 11():761960. PubMed ID: 34888242
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
    Gallon J; Loomis E; Curry E; Martin N; Brody L; Garner I; Brown R; Flanagan JM
    Clin Epigenetics; 2021 Jun; 13(1):122. PubMed ID: 34090482
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
    Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.
    Matte I; Garde-Granger P; Bessette P; Piché A
    Am J Cancer Res; 2019; 9(1):160-170. PubMed ID: 30755819
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 73. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.
    Özeş AR; Miller DF; Özeş ON; Fang F; Liu Y; Matei D; Huang T; Nephew KP
    Oncogene; 2016 Oct; 35(41):5350-5361. PubMed ID: 27041570
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
    Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
    Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
    Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
    [No Abstract]   [Full Text] [Related]  

  • 77. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
    Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer.
    Ni J; Wang Y; Cheng X; Teng F; Wang C; Han S; Chen X; Guo W
    Cancer Manag Res; 2020; 12():11085-11093. PubMed ID: 33173341
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer.
    Ahn B; Moon D; Kim HS; Lee C; Cho NH; Choi HK; Kim D; Lee JY; Nam EJ; Won D; An HJ; Kwon SY; Shin SJ; Jung HR; Kwon D; Park H; Kim M; Cha YJ; Park H; Lee Y; Noh S; Lee YM; Choi SE; Kim JM; Sung SH; Park E
    Nat Commun; 2024 May; 15(1):4253. PubMed ID: 38762636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.